

ABSTRACT

Trastuzumab, a second anti-HER2 antibody and a chemotherapeutic agent are combined to treat HER2-positive advanced gastric cancer. Compared with existing first-line treatment solutions for HER2-positive advanced gastric cancer, the combined treatment method of trastuzumab, the second
5 anti-HER2 antibody and the chemotherapeutic agent (XELOX) prolongs the progression free survival (PFS) and/or the overall survival (OS) of patients.

No Figure